AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). - Wikidata - wikimedia - TriplyDB

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

http://www.wikidata.org/entity/Q39775573

about

Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft.Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.Picropodophyllin and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.Hepatocellular carcinoma: insight from animal models.Effects of α-tocopherol and β-carotene supplementation on liver cancer incidence and chronic liver disease mortality in the ATBC study Liver cancer: Targeted future options Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control.Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.Tyrosine kinase inhibitors to treat liver cancer.Developing better treatments in hepatocellular carcinoma.Latest developments in targeted therapy for hepatocellular carcinoma.Nonalcoholic fatty liver disease in India - a lot done, yet more required!The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma.Pharmacological agents for NASH.Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy.Hepatocellular carcinoma: systemic therapies and future perspectives.A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma.Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts.Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma.EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib.Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.Effect of TALEN-mediated IL-6 knockout on cell proliferation, apoptosis, invasion and anti-cancer therapy in hepatocellular carcinoma (HCC-LM3) cells.A novel mouse model of nonalcoholic steatohepatitis with significant insulin resistance.Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems.Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma.Current Development Status of MEK Inhibitors.

P2860

Q26766689-6F48F1FD-359B-4D86-B1DC-00FA46B11204 Q30372076-24E60A69-46DD-436F-BD64-F845A55306E0 Q33709656-106E4BDF-56EE-4063-919E-9A1E85D68635 Q34104350-2E4BE209-2310-460D-9F54-AC2AF340A49E Q34131801-1F642D40-2C3E-4909-A5EE-72197D654D91 Q34241371-C8C0B45C-B643-4810-A3DA-9687968774A0 Q34292802-02CD5E8F-96A3-4DFE-90B4-0614CA292AB6 Q34584872-D407D3AD-897F-4072-9D5A-B619E4BF4D99 Q34633249-45D71320-B78B-42FC-B842-AB1A59B897ED Q34687005-5DAF7F86-F890-4726-A098-53EC20083F02 Q34695180-716972B4-5AC1-4F58-9165-15A847015741 Q34837850-14D316ED-784A-4F8D-8638-AB76506C59BD Q35828564-30FC8F25-34B3-4FCD-AFB1-80DCD31B1268 Q35836350-C3A3DA58-F930-4B76-9F21-D227E8D6C4B1 Q36299617-8DF390F3-B593-4C4B-8038-09E9E7D81B0F Q36362544-40785DA6-77F9-4A3B-B18E-6A356C8CF04D Q37030376-B14B421A-3542-47FE-9E66-1AF9FAEB0582 Q37686529-4E452A0F-BB68-494D-B921-8355E1FB0F14 Q37798817-F8C4ECB3-AA46-47B7-B817-2BA6049AD5DC Q37799829-25F8B673-5B2D-4F7B-AA60-0908168DB15F Q37824619-15715082-863B-4168-AA95-D91657F7F66E Q37950012-1ED2CC0E-3182-4988-ACEB-C7F6B1896ADB Q38152646-3CD5B492-BE92-46A6-9F06-0EE44C7A48A3 Q38184582-ADFBDBC5-48C4-4EBD-92D3-28868B1E8C07 Q38246965-283648AB-651C-48DF-BD50-0B88DDEF1CFD Q38387061-3B84F86F-4BB5-48CE-8353-88CA05421204 Q38444096-7DC24074-2585-4A80-B287-14D0862C50E0 Q38635603-84A82777-3330-47E6-AB7B-CB2168677402 Q38946509-98AAEE80-A3EE-4DFE-A460-4CFDC7755CC0 Q38972744-C01C943F-86A9-453B-8199-E938C3E44765 Q39270291-A6C09B90-E8E1-4F2E-8E7E-EF997D052B32 Q39362619-9FDB99DF-57CF-4734-BFF4-9C5BFBA30D92 Q39424703-347D9BC2-FE5E-4991-A2EC-7199B0D6FF33 Q39499156-5A4C705A-CA3B-4E65-A91F-D69E2D1B96A1 Q42437883-24E5CF1D-8AA9-4E76-AABA-2E0A22F9BC59 Q42914421-692E2FF0-2BEF-43D7-8067-F176BCA43802 Q44372454-E13A41E4-0E63-4F00-948D-5F52AE3767EE Q47123785-B010B7D3-21FD-401A-8344-381502895FCB Q47141545-CA82EDFF-1EBB-43FD-B598-1C8F61AD4AFD Q47735535-8ED0FC86-2E17-445A-9983-451BBFB1CF65

P2860

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

http://www.wikidata.org/entity/Q39775573

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

AZD6244 enhances the anti-tumo ...... epatocellular carcinoma (HCC).

@en

AZD6244 enhances the anti-tumo ...... human hepatocellular carcinoma

@nl

type

label

AZD6244 enhances the anti-tumo ...... epatocellular carcinoma (HCC).

@en

AZD6244 enhances the anti-tumo ...... human hepatocellular carcinoma

@nl

prefLabel

AZD6244 enhances the anti-tumo ...... epatocellular carcinoma (HCC).

@en

AZD6244 enhances the anti-tumo ...... human hepatocellular carcinoma

@nl

P1433

Q39775573-28DB69A3-4400-454E-9CE3-F6E25CD11A1E

P1476

Q39775573-1132AF05-4E6B-4280-88AB-629D9261033B

P2093

Q39775573-0EC4A321-05DC-466C-A8F0-CE9CCBF6F670

Q39775573-22FDA053-0C79-4443-8CA0-A1A1DF4A9FCC

Q39775573-2E70C1EA-B3C7-4F00-8E06-42A4CD97688C

Q39775573-346C4616-223A-4BD5-90AF-4B27BF80608C

Q39775573-3663A006-06D6-4153-BB06-260595D848EF

Q39775573-513C833B-CF96-49F8-8ABB-168BBE93B678

Q39775573-51BEEAE9-0C33-46E2-912B-2AEF2719811C

Q39775573-5504A4C6-9E2D-4AB3-A904-B426B826840C

Q39775573-576D703F-7FAC-4650-8B26-A490416825D3

Q39775573-B3A5E8D3-697C-4113-8F3C-B25BD8D600E6

P304

Q39775573-6138F816-5E87-4D8C-9DA2-B67CAB3456C9

P31

Q39775573-0FBB1142-63AD-479E-A123-AE3C9EC12B05

P356

Q39775573-3EE84522-0B0E-4B3F-9CB9-AA070A6A9912

P433

Q39775573-1FD1870D-D3E0-4019-AE8F-C136371E370F

P478

Q39775573-324CD6C1-A936-460A-A0D0-7D1B0A6E65ED

P50

Q39775573-1F54CCF1-403C-4019-B524-AC29EAC8925A

Q39775573-1FC6B1C9-1681-46CB-92AF-B42925141A0D

P577

Q39775573-894529B9-28AA-4BF6-B09C-04D37F66024D

P698

Q39775573-224201D1-F536-46DB-903E-DE60AC5E2FC6

P356

J.JHEP.2009.10.008

P1433

Journal of Hepatology

P1476

AZD6244 enhances the anti-tumo ...... hepatocellular carcinoma (HCC)

@en

P2093

Alexander Chung

http://www.w3.org/2001/XMLSchema#string

Boon Cher Goh

http://www.w3.org/2001/XMLSchema#string

Choon Hua Thng

http://www.w3.org/2001/XMLSchema#string

Donald Poon

http://www.w3.org/2001/XMLSchema#string

Han Chong Toh

http://www.w3.org/2001/XMLSchema#string

Heng Nung Koong

http://www.w3.org/2001/XMLSchema#string

Hock Soo Ong

http://www.w3.org/2001/XMLSchema#string

Khee Chee Soo

http://www.w3.org/2001/XMLSchema#string

Paul D Smith

http://www.w3.org/2001/XMLSchema#string

Pierce Chow

http://www.w3.org/2001/XMLSchema#string

P304

79-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JHEP.2009.10.008

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19910069

http://www.w3.org/2001/XMLSchema#string